Download PDF
Thromb Haemost 1966; 16(03/04): 574-585
DOI: 10.1055/s-0038-1655646
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Deficiencies and Inhibitors of Thromboplastic Activity

G. F Grannis   *
1   Cardeza Foundation for Hematological Research, Jefferson Medical College, Philadelphia, Pennsylvania
,
L. A Kazal
1   Cardeza Foundation for Hematological Research, Jefferson Medical College, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

The effects of hereditary deficiencies of thromboplastic proteins (hemophilia A and B) on the time course of thrombin appearance and disappearance in plasma (the thrombin activity curve, TAC) were compared with the effects of a naturally occurring gamma-globulin inhibitor of thromboplastic activity and with an anti-thromboplastic activity derived from cephalin (phosphatidylserine-lipoprotein complex).

Both inhibitors inhibit reactions involving the protein in which hemophilia A plasma is deficient (factor VIII).

* Present address: Temple University Medical Center, Broad and Ontario Streets, Philadelphia, Pennsylvania.


 

  • References

  • 1 Tocantins L. M. Cephalin, Protamine and the Antithromboplastic Activity of Normal and Hemophilic Plasmas. Proc. Soc. exp. Biol. (N. Y.) 54: 94 1943;
    CrossrefPubMedGoogle Scholar
  • 2 Tocantins L. M. Influence of the Contacting Surface on the Coagulability and Anticephalin Activity of Normal and Hemophilic Plasmas. Amer. J. Physiol 143: 67 1945;
    PubMedGoogle Scholar
  • 3 Tocantins L. M. Hemophilic Syndromes and Hemophilia. Blood 9: 281 1954;
    PubMedGoogle Scholar
  • 4 Kazal L. A, Miller O. P, Turner D. L, Tocantins L. M. Solubilization of Phosphatidyl Serine by Human Lipoprotein with Development of Anticephalin Anticoagulant activity. Fed. Proc 21: 59 1962;
    PubMedGoogle Scholar
  • 5 Kazal L. A. Interactions of Phospholipids with Lipoproteins, with Serum and its Proteins, and with Proteolytic and Nonproteolytic Enzymes in Blood Clotting. Trans. N.Y. Acad. Sci 27: 613 1965;
    CrossrefPubMedGoogle Scholar
  • 6 Marcus A. J, Spaet T. H. Platelet Phosphatides: Their Separation, Identification and Clotting Activity. J. clin. Invest 37: 1836 1958;
    CrossrefPubMedGoogle Scholar
  • 7 Silver M. J, Turner D. L, Tocantins L. M. Phospholipid Antithromboplastin-Assay in vitro and Evaluation in vivo of Purified Fractions. Amer. J. Physiol 190: 8 1957;
    PubMedGoogle Scholar
  • 8 Spaet T.H. Anticoagulants from Platelets. J. appi. Physiol 18: 325 1957;
    PubMedGoogle Scholar
  • 9 Munro F. L, Munro M. P. Elektrophoretic Isolation of a Circulating Anticoagulant. J. clin. Invest 25: 814 1946;
    CrossrefPubMedGoogle Scholar
  • 10 Margolius J. A, Jackson D. P, Ratnoff O. D. Medicine. (Baltimore) 40: 145 1961;
    PubMedGoogle Scholar
  • 11 Stefanini M, Dameshek W. The Hemorrhagic Disorders. Chap. 8. Grune and Stratton; New York: 1962
    Google Scholar
  • 12 Leitner A, Bidwell E, Dike G. W. R. An Antihaemophilic Globulin (Factor VIII) Inhibitor: Purification, Characterization and Reaction Kinetics. Brit. J. Haemat 9: 245 1963;
    CrossrefPubMedGoogle Scholar
  • 13 Tocantins L. M, Holburn R. R, Carroll R. T. In: Blood Coagulation, Hemorrhage and Thrombosis. Tocantins L. M, and Kazal L. A. eds. 298. Grune and Stratton; New York: 1964
    Google Scholar
  • 14 Kazal L. A, Amsel S, Miller O. P, Tocantins L. M. The Preparation and some Properties of Fibrinogen Precipitated From Human Plasma. Proc. Soc. exp. Biol. (N. Y.) 113: 989 1963;
    CrossrefPubMedGoogle Scholar
  • 15 Sober H. A, Petersen E. A. Fed. Proc 17: 1116 1958;
    PubMedGoogle Scholar
  • 16 Kazal L. A. Tocantins In: Blood Coagulation, Hemorrhage and Thrombosis. Tocantins L. M, and Kazal L. A. eds. 353 Grune and Stratton; New York: 1964
    Google Scholar
  • 17 Grannis G. F, Kazal L. A, Tocantins M. The Spectrophotometric Determination of Thrombin Activity in Plasma, Thrombos. Diathes. haemorrh. (Stuttg.) 13: 330 1965;
    PubMedGoogle Scholar
  • 18 Kazal L. A, Grannis G. F, Tocantins L. M. The Reactions of Thrombin with Fibrinogen and Plasma Antithrombin. Thrombos. Diathes. haemorrh. (Stuttg.) 13: 343 1965;
    PubMedGoogle Scholar
  • 19 Ferguson J. H. In: Blood Coagulation, Hemorrhage and Thrombosis. Tocantins L. M, and Kazal L. A. eds. 315 Grune and Stratton; New York: 1964
    Google Scholar
  • 20 Biggs R. In: Biological Aspects of Occlusive Vascular Disease. Chalmers D. G, and Gresham G. A. eds. 261 Cambridge University Press; 1964
    Google Scholar
  • 21 Grannis G. F, Kazal L. A. Prothrombin and Antithrombin: Their Opposing Functions in Blood Coagulation. Thrombos. Diathes. haemorrh. (Stutt.) 16: 497 1966;
    PubMedGoogle Scholar
  • 22 Wright I. S. Nomenclature of Blood Clotting Factors. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 381 1962;
    PubMedGoogle Scholar
  • 23 Surgenor D. M, Steele B. B, Wallach D. F. H. Thrombin Formation in Purified Systems. Thrombos. Diathes. haemorrh. (Stuttg.) 3: 214 1959;
    PubMedGoogle Scholar
  • 24 Macfarlane R.G. An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier. Nature (Lond.) 202: 498 1964;
    CrossrefPubMedGoogle Scholar
  • 25 Davie E. W, Ratnoff O. D. Waterfall Sequence for Intrinsic Blood Clotting. Science 145: 1310 1964;
    CrossrefPubMedGoogle Scholar
  • 26 Kazal L. A. Coagulation Proteins. In: The Serum Proteins and the Dysproteinemias. Sunderman F. W, and Sunderman Jr. F. W. eds. Chap. 29. Lippincott; Philadelphia: 1964
    Google Scholar
  • 27 Seegers W. H. Basic Enzymology of Blood Coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) 13: 575 1965;
    PubMedGoogle Scholar
  • 28 Ratnoff O. D. Estimation of Hageman Factor in Plasma or Plasma Fractions in Blood Coagulation, Hemorrhage and Thrombosis. Tocantins L. M, and Kazal L. A. eds. 141 Grune and Stratton; New York: 1964
    Google Scholar